THE MEDICINE
Ibogaine
A medicine with profound potential for veterans navigating addiction, PTSD, and traumatic brain injury — at the heart of our work for over 25 years.
ON THIS PAGE
What It Is
Why People Are Paying Attention
What a Session Is Like
How It May Work
Legal Status & Access
Safety
What the Evidence Says
Why Donors Matter
01
What It Is
Ibogaine is a naturally occurring psychoactive compound derived from the root bark of the iboga shrub (Tabernanthe iboga), native to Central Africa. The iboga plant has a long history of traditional medicinal and ceremonial use in parts of Central Africa, including Gabon, Cameroon, and the Republic of Congo.
02
Why People Are Paying Attention
Researchers and clinicians are exploring ibogaine for its potential to help with substance use disorders (especially opioid addiction), post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI).
03
What a Session Is Like
Ibogaine sessions can be intense, long (often 24+ hours), and psychologically demanding—often described as a lucid, dream-like review of life experiences, including trauma.
04
How It May Work
Reported effects include reducing opioid withdrawal symptoms and lowering craving. Scientists hypothesize effects on neuroplasticity (the brain's capacity to "rewire"), potentially enabling new perspectives and behavior change—especially when paired with strong clinical support. Note: Biological mechanisms and durability of benefits still require rigorous trials.
05
Legal Status & Access
Ibogaine is illegal under U.S. federal law (Schedule I). People seeking treatment often travel outside the U.S. to jurisdictions where it is legal or unregulated. Private clinics commonly cite pricing around ~$15,000 per treatment (often excluding travel).
06
Safety
The most serious known risk is cardiac toxicity, including dangerous (potentially fatal) arrhythmias. (The New York Times, 2024-03-05) Risk may be reduced through pre-screening, avoiding contraindicated medications, and continuous cardiac monitoring (ECG)—but risk cannot be eliminated
07
What the Evidence Says
Much published evidence comes from small studies and observational reports, not large placebo-controlled trials. (The New York Times, 2024-03-05) The field needs more research on who benefits most, how long benefits last, best-practice protocols, and integration/aftercare.
08
Why Donors Matter
Responsible evaluation and potential accessibility require high-quality clinical research, ethical protocols, medical safety infrastructure, and training for integration and long-term outcome tracking.
BEGIN